ImmunoGen bags ADC deal with Novartis

Antibody-drug conjugate superstar ImmunoGen ($IMGN) has signed another agreement to lend its targeted drug technology to Novartis ($NVS) for an undisclosed cancer therapy. The latest license is part of a 2010 deal between the two, under which ImmunoGen could reap $200 million plus royalties on any approved drugs. More